BibTex format
@article{Maher:2024:10.3310/lywq8541,
author = {Maher, TM and Tudor, VA and Saunders, P and Zanghelini, F and Grossi, Sampedro C and Xydopoulos, G and Gibbons, M and Fletcher, SV and Denton, CP and Kokosi, M and Hoyles, RK and Parfrey, H and Renzoni, EA and Wells, AU and Ashby, D and Fordham, RJ and Szigeti, M and Molyneaux, PL},
doi = {10.3310/lywq8541},
journal = {Efficacy and Mechanism Evaluation},
pages = {1--68},
title = {Rituximab compared to intravenous cyclophosphamide in adults with connective tissue disease-associated interstitial lung disease: the RECITAL RCT},
url = {http://dx.doi.org/10.3310/lywq8541},
year = {2024}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - <jats:sec id="abs1-1"><jats:title>Background</jats:title><jats:p>Interstitial lung disease frequently complicates systemic autoimmune disorders including scleroderma, idiopathic inflammatory myositis and mixed connective tissue disease, resulting in considerable morbidity and mortality. Based on the results of trials undertaken in scleroderma, cyclophosphamide is the standard of care for individuals with severe or progressive connective tissue disease-associated interstitial lung disease. Observational studies suggest that the anti-CD20 monoclonal antibody, rituximab is an effective rescue therapy in treatment of refractory connective tissue disease-associated interstitial lung disease, but it has not been studied as first-line therapy in clinical trials.</jats:p></jats:sec><jats:sec id="abs1-2"><jats:title>Objectives</jats:title><jats:p>To compare the safety and efficacy of rituximab against that of cyclophosphamide as treatment for individuals with severe, progressive interstitial lung disease associated with scleroderma, idiopathic inflammatory myositis or mixed connective tissue disease.</jats:p></jats:sec><jats:sec id="abs1-3"><jats:title>Methods</jats:title><jats:p>This was a Phase IIb, multicentre, randomised, double-blind, double-dummy study assessing the superiority of rituximab compared with cyclophosphamide, conducted in rheumatology or interstitial lung disease units at 11 UK centres. The study recruited individuals with extensive and/or progressive connective tissue disease-associated interstitial lung disease, excluding those with significant comorbidities, including airflow obstruction. Participants were randomised 1 : 1 to receive either rituximab 1 g given intravenously, twice at an interval of 2 weeks, or intravenous cyclophosphamide given monthly for 6 months at a dose of 600 mg/m<jats:sup>2</jats:sup> body surf
AU - Maher,TM
AU - Tudor,VA
AU - Saunders,P
AU - Zanghelini,F
AU - Grossi,Sampedro C
AU - Xydopoulos,G
AU - Gibbons,M
AU - Fletcher,SV
AU - Denton,CP
AU - Kokosi,M
AU - Hoyles,RK
AU - Parfrey,H
AU - Renzoni,EA
AU - Wells,AU
AU - Ashby,D
AU - Fordham,RJ
AU - Szigeti,M
AU - Molyneaux,PL
DO - 10.3310/lywq8541
EP - 68
PY - 2024///
SN - 2050-4365
SP - 1
TI - Rituximab compared to intravenous cyclophosphamide in adults with connective tissue disease-associated interstitial lung disease: the RECITAL RCT
T2 - Efficacy and Mechanism Evaluation
UR - http://dx.doi.org/10.3310/lywq8541
UR - https://doi.org/10.3310/lywq8541
ER -